Retatrutide (5mg) Dosage Protocol
Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials demonstrated up to 24% body weight reduction.
Add 2.0 mL bacteriostatic water → 2.5 mg/mL
1mg-12mg once weekly (dose escalation required)
At 2.5 mg/mL: 40 units = 1mg, 80 units = 2mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 1mg weekly | 40 units (0.4 mL) |
| Weeks 5-8 | 2mg weekly | 80 units (0.8 mL) |
| Weeks 9-12 | 4mg weekly | Use 10mg vial |
| Weeks 13-16 | 6-8mg weekly | Use larger vials |
| Week 17+ | 8-12mg weekly | Maximum studied dose |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall to prevent foaming
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Retatrutide is a first-in-class triple-agonist that activates GLP-1, GIP, and glucagon receptors. The glucagon component may increase energy expenditure beyond what GLP-1/GIP agonists achieve alone. Phase 2 trials showed 12mg weekly resulted in up to 24% body weight loss at 48 weeks without plateau.
- Triple-receptor agonist mechanism (GLP-1/GIP/Glucagon)
- Phase 2 trials showed up to 24% weight loss
- Potential for enhanced metabolic effects
- Once-weekly dosing convenience
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526
- Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Lancet. 2022;400(10366):1869-1881
- ClinicalTrials.gov NCT04881760 - Phase 2 Study of LY3437943
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Investigational compound - handle with care
- •Investigational compound - not FDA approved
- •Phase 3 TRIUMPH trials ongoing
- •Escalate dose every 4 weeks as tolerated
- •GI side effects common during titration
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.